Analysts and professional investors may also participate in the meeting by conference call. A webcast of the meeting will be available on YM's website: www.ymbiosciences.com.
Meeting/Conference Call Details: DATE: December 6, 2010 TIME: 12:30 pm Eastern Time DIAL IN NUMBER: (647) 427-7450 or (888) 231-8191 MEETING LOCATION: Hilton Orlando, Lake Sheen A Room
CYT387 is an inhibitor of the kinase enzymes JAK1 and JAK2, which have been implicated in a family of hematological conditions known as myeloproliferative neoplasms, including myelofibrosis, and as well in numerous other disorders including indications in hematology, oncology and inflammatory diseases. Myelofibrosis is a chronic debilitating disease in which a patient's bone marrow is replaced by scar tissue and for which treatment options are limited or unsatisfactory. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CYT387 for the treatment of myelofibrosis.
YM BioSciences retains the global commercialization rights to CYT387.
About YM BioSciences
YM BioSciences Inc. is a drug development company advancing three clinical-stage products: CYT387, a small molecule, dual inhibitor of JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a potent vascular disrupting agent (VDA).
CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated in a number of immune cell disorders including myeloproliferative disorders and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis with positive interim safety and activity data reported at the American Society of Hematology (ASH
|SOURCE YM BioSciences Inc.|
Copyright©2010 PR Newswire.
All rights reserved